Skip to content
Back to announcement

20251120_BMHS_Public Expose_31986682_lamp2.pdf

Other Text extracted BMHS

Source file signed link, expires in 15 minutes

This browser can't display the PDF inline. Open it in a new tab.

Extracted text 36

Page 1
PT Bundamedik Tbk
Public Expose – 9M25 Results


Nov 2025
Page 2
I. Financial Update – 9M25
II. Investment Highlights
Page 3
9M25 Results
Page 4
                                       Financial & Operational Performance
                                                    HIGHLIGHTS OF CONSOLIDATED RESULT
                                                                                                                    1.   Operational:
               Details       2Q25      3Q25     QoQ (%)   3Q24      3Q25     YoY (%)    9M24     9M25     YoY (%)         3Q25 vs 2Q25
OPERATIONALS ('000)
                                                                                                                          • Hospitals showed 7% growth QoQ for OPT and 6% growth QoQ for IPT coming
# Outpatient                   142       152         7%      154       152      -1%        460      442       -4%            from BPJS and non-BPJS segment.
# Inpatient Days                30        32         6%       29        32      10%         93       93        0%         • BOR also improved to 53% compared to 50% in previous period.
# Inpatient Admission           12        12         6%       11        12       9%         35       35        0%         • Morula: Total cycle grew by 7% due continuous momentum from anniversary.
# Surgery                      4.0       4.2         6%      3.8       4.2      11%       11.1     12.0        8%         • Diagnos: Volume grew by 7% YoY driven by corporate project.
# Beds                         656       656         0%      631       656       4%        631      656        4%         3Q25 vs 3Q24
BOR (%)                        50%       53%         2%      50%       53%       3%        54%      52%       -2%         • For Hospitals, IPT showed a strong growth from BPJS (11% YoY) and non -BPJS
# IVF Cycles                   1.2       1.2         7%      1.2       1.2       4%        3.7      3.5       -5%            (6% YoY).
# Lab Test (Diagnos)           217       232         7%      206       232      12%        639      621       -3%         • BOR also improved to 53% compared to 50% in previous period.
PROFIT LOSS (Rp Bn)                                                                                                       • Morula: Total cycle grew by 4% due to marketing efforts, anniversary momentum
Gross Revenue                   379       397        5%      372       397       7%      1,157    1,155        0%            from Lyora and package.
Net Revenue                     317       337        6%      314       337       7%        985      971       -1%         • Diagnos: Volume grew by 12% YoY driven by corporate project and Group’s
Gross Profit                    174       194       12%      175       194      11%        545      538       -1%            synergy.
GPM (%) to gross                46%       49%                47%       49%                 47%      47%
EBITDA                            50       67       35%        52       67      28%        175      170       -3%   2.   Financials:
EBITDA Margin (%) to gross      13%       17%                14%       17%                 15%      15%                    3Q25 vs 2Q25
Net Profit                       1.3     13.6      950%       1.5     13.6     782%       20.2     20.0       -1%          • Revenue grew by 5% aligned with higher hospital traffic, aligned with higher
NPM (%) to gross               0.3%      3.4%               0.4%      3.4%                1.7%     1.7%                       number of surgery, corporate project, and Morula’s anniversary.
                                                                                                                           • GPM improved to 49% due to efficiency on the pharmacy cost and trickled down
                                                                                                                              to EBITDA of Rp67 bn or translated into 17% EBITDA Margin.
                                                                                                                           3Q25 vs 3Q24
                                                                                                                           • Overall revenue grew by 7% YoY driven by Hospitals and Morula.
                                                                                                                           • Hospitals revenue grew by 7% YoY, mainly driven by existing hospitals (RSU BJ,
                                                                                                                              RSU BM, RSIA BC), while new hospitals recorded a 36% YoY growth, supported by
                                                                                                                              an uptick in surgery and seasonal disease cases during 3Q.
                                                                                                                           • Morula also booked 7% growth in revenue in line with higher number of cycle
                                                                                                                              booked in 3Q25 compared to 3Q24.
                                                                                                                           • Gross profit grew by 11% due to lower COGS growth compared to revenue growth,
                                                                                                                              driven by improved pharmacy costs.
                                                                                                                           • Improvement on the EBITDA margin to 17% due to 1% GPM improvement and
                                                                                                                              OPEX efficiency.
Page 5
                                   Operational & Financials Highlights
           Outpatient (‘000)                                  Inpatient (‘000)                                 IVF Cycles (‘000)                               Lab Test (‘000)
                  -1%                                                9%
                                                                                                                                                                   +12%
                          +7%                                                                                        +4%
                                                                           +6%
                                                                                                                             +7%                                             +7%
      154          142           152
                                                       11            12            12
                                                                                                                                     1.2                 206          217            232
                                                                                                         1.2          1.2




     3Q24          2Q25         3Q25                  3Q24         2Q25          3Q25                  3Q24          2Q25            3Q25               3Q24         2Q25           3Q25


Financials (in Rp Bn)
                 Revenue                                     Gross Profit                                         EBITDA                                          Net Profit
                  +7%                                47%                           49%          % margin 14%                       17%
                                                                    46%                                             13%                                            +782%
                          +5%                   % margin
                                                                                                                  +28%
                                                                +11%
     372           379            397                                     +12%                                              +35%                                            +950%


                                                       175          174          194                                                67                                              13.6
                                                                                                        52           50

                                                                                                                                                         1.5          1.3

     3Q24          2Q25          3Q25                 3Q24         2Q25          3Q25                 3Q24         2Q25            3Q25                 3Q24         2Q25           3Q25


 •   Hospitals volume slight dropped on OPT due to lower BPJS traffic, however non-BPJS showed 3% growth. IPT showed a strong growth from BPJS (11% YoY) and non -BPJS (6% YoY).
 •   Total cycle grew by 4% due to marketing efforts, anniversary momentum from Lyora and package.
 •   Lab Test grew by 12% YoY driven by corporate project and Group’s synergy.
 •   3Q Revenue grew by 7% YoY driven by Hospitals and Morula due to uptick on surgery, higher cycle booked from Morula and seasonal disease.
 •   3Q Gross profit grew by 11% YoY due to lower COGS growth compared to revenue growth, driven by improved pharmacy costs.
 •   Improvement on the 3Q EBITDA margin to 17% due to 1% GPM improvement and OPEX efficiency.
Page 6
                                                                      Balance Sheet
                                                                       Remains healthy
                                      CASH VS DEBT                                                            NET DEBT-TO-EBITDA
                                             (Rp B)                                                                       (x)
Net      ------       ------
Debt     -135         -216        225            405           308               380
                                                                                   1,190
                                                      1,027         1,091                                                        1.9x
                                                                                                                                         1.4x    1.7x
                     830               855                    783            811
        625                613   629            622                                                                0.7x
               490

                                                                                                 -0.6x    -0.4x

         2020         2021        2022           2023          2024           9M25               2020     2021     2022          2023    2024   9M25


   AR Days                                                                  WORKING CAPITAL DAYS
   Inventory Days     53
   AP Days                                            46                               43                40                                39
   29                            29                             30                                                30                32                  29
                                                                                            28
                                                                            16                    19                        19                   19
              10                         13



              2020                       2021                               2022                 2023                     2024                  9M25
Page 7
Investment Highlights
 1 Strategic Ecosystem Healthcare Synergy
   2 Organization Fundamental Improvement
    3 Customer Perception & Trust
    4   Strengthen COE of Women & Children

   5 Leading Healthcare Innovation through Centers of Excellence
 6 Maximizing Current Asset Utilisation
Page 8
1. STRATEGIC ECOSYSTEM HEALTHCARE SYNERGY
  • Bundamedik Ecosystem
  • Creating Synergy across the BMHS Healthcare Ecosystem
  • From Hospitals to Holistic Healthcare Ecosystem
Page 9
   Bundamedik Tbk (BMHS)
   Ecosystem
                                     IVF Clinics



                                                                                                                                                                                                                              Expanding Presence
                 Women & Children                     Diagnostic Lab
                     Hospitals


                                                                                                                                                                                                                              10 HOSPITALS
                                                                        Medical                    PADANG
Bunda Hospitals
                                                                       Evacuation

                                                                                                                                                                                   PONTIANAK
                                                                                                                                                                                                                              11 IVF CLINICS
                                                                                                                                                 BATAM

                                                                                                  RSU BUNDA PADANG
                                                                                                                                          PALEMBANG
                                                                                                                                                                   RSIA AZ ZAHRA
                                                                                                                                                                   (PALEMBANG)                                                35 LABORATORIES
                                                                                                                                                                                                      RSIA BUNDA   MAKASSAR
                                                                                                                                                                                                       DENPASAR
   BIC Clinics                                                         Pharmacy


                                                                                                                                                                                                                              3k++ CLINICS NETWORK
                                                                                                                                                                              YOGYAKARTA
                                                                                                                                                                                                                                   (KLINIK PINTAR)
                                                                                                                                     JAKARTA, DEPOK,
                                                                                                       RSIA              RSU            TANGERANG,         BANDUNG
                  Medical Tourism                   Medical Training                               BUNDA JAKARTA     BUNDA JAKARTA                                                   SURABAYA
                                                                                                                                              BEKASI
                       Board                           Program
                                                                                                                                                                                                                              92   FERTILITY CLINICS
                                                                                                                                                                                                                                   NETWORK (KFI)
                                                                                                                                                                                                      BALI

                                    Dental Clinic
                                                                                                                                                                              RSIA PUSURA TEGALSARI




                                                                                    RSU BUNDA MARGONDA   RSIA BUNDA CIPUTAT     RSU CITRA        RSJP Paramartha
                                                                                                                              HARAPAN BEKASI        BANDUNG
Page 10
Creating Synergy across the BMHS Healthcare Ecosystem
Page 11
                           Creating Synergy across the BMHS Healthcare Ecosystem
                                       Women & Children                          Life Style                     General (Adult - Geriatric)




                                        Fertility Products                     ART Products                          Health Products




                                     Reproductive Genomics                    Nutri Genomics                         Onco Genomics




The Company is building the Bundamedik Healthcare Systems (BMHS) ecosystem to provide comprehensive health services, with service coverage:




                                     RS Bunda Group provides health services including maternity, pediatric, oncology, Heart Center,
                                     Robotic Surgery, Endocrine Center, Endoscopy Center, GynROSE Clinic, geriatrics supported by modern
                                     medical technology. Currently the Company operates 5 maternity and children hospitals, 4 general
                                     hospitals, and 1 cardiovascular hospital.
Page 12
                                        From Hospitals to Holistic Healthcare Ecosystem

Revenue Per payor in Hospital:

                              1Q23
                              9M24                                    1H24
                                                                       9M25                Hospitals improvement perspective:
                                                                                           •    Improved +2.3pps in Corp & Ins from our hospital in
                                                                                                Jakarta & Bali area mostly serve Corp & Ins patient
  BPJS                           22.5%                                      23.3%
                                                                                           •    While Bunda is best known for OBGYN and Pediatrics, we
  OOP                 40.9%                                   43.2%                             are actively developing other COEs.
  Corp & Ins                                                                               •    Revenue contribution from non OBGYN and Pediatric in
                                                                                                9M25 was 49%.
                                36.5%                                       33.5%




                                           New hospitals still gaining positive traction…
     Surgery (‘000)                        OPT (‘000)                         IPT (‘000)
                                                                                                                REVENUE                  EBITDA
               +48%                          +47%                              +37%
                       4                                 84

    2
                2
                                      39
                                               62
                                                                        7
                                                                                    11
                                                                                           14
                                                                                                                23%                         41%
                                                                                                                        9M25 vs 9M24
  9M23         9M24   9M25           9M23    9M24       9M25          9M23     9M24      9M25
Page 13
                                        From Hospitals to Holistic Healthcare Ecosystem



                                IVF CYCLE Growth                              Revenue (in Rp Bn)

              +8%                                    0%                              +7%

                   +11%
                                                          +2%                            +9%
                          701            539       527          537                            125
    648      632                                                       117         115




    3Q24    2Q25      3Q25              3Q24       2Q25         3Q25   3Q24       2Q25         3Q25
       Fresh Cycle                         Frozen Cycle                       Revenue

•   IVF revenue rose +7% YoY, led by +8% growth in Fresh Cycles.
•   3Q25 performance regained momentum following Morula’s 27th Anniversary campaign.
•   Special PGTA bundling program contributed to patient engagement and volume uplift.
Page 14
                       From Hospitals to Holistic Healthcare Ecosystem

9M INITIATIVES

                                                 Launching AI generated                   1ST private lab to launch:
  #160 new lab tests   Synergy with RSIA Bunda
                          Jakarta & Morula           Smart MCU Report                             Arbovirus



                                                 •   Partnership with Helix clinic to have joint operation for Laboratorium
                                                 •   Opening an Outlet in RSIA Andini Pekanbaru
                                                 •   Synergy with RSIA BJ and Morula for Non-Invasive Prenatal Test (NIPT)
                                                     and Preimplantation Genetic Testing for Aneuploidies (PGTA).
                                                 •   Overall, from all the initiatives, Diagnos have booked 7% increased QoQ
                                                     and 12% increased YoY in volume.



                                                                    +12%                                       -2%


                                                                           +7%                                    +4%

                                                                     217         232            42           40             41
                                                         206



                                                        3Q24        2Q25         3Q25          3Q24        2Q25            3Q25
                                                                Volume (‘000)                         Revenue (in Rp Bn)
Page 15
2. ORGANIZATION FUNDAMENTAL IMPROVEMENT
•    Incorporating Healthy Work Environment
•   Shaping Future Leadership – Talent Management
•   Promoting Equal Opportunity for Leadership
•   Improvement on Employee Turnover Rate
•   ESG Framework
•   ESG - A workplace that cares about breastfeeding mothers
Page 16
Incorporating Healthy Work Environment
Page 17
                Shaping Future Leadership - Talent Management

Identify High Potential                   Identify High Potential                                   Talent Development & Retention

                                                        • Group of Leaders (All Chief &
                                                          President Director)
                                                        • Validate & decide who has
                                                          high potential, who could be
                                                          future leaders, and what
                                                          development actions needed
                             Talent Committee
                                                                                               A Talent Development Program is a focused effort to grow
                                  Succession Identification                                    high-potential employees. This program is tailored specifically
                                                                                               for identified talents, considering their role relevance,
                                                                                               personal motivation, and active support from their manager
                                                                                               to prepare them for future leadership or critical positions.




                                                                                               Talent Retention & Engagement is the effort to keep top
                                                                                               talent motivated and committed by providing consistent
                              Succession planning is the process of preparing employees
                                                                                               guidance from leaders or mentors, along with clear career
                              to take on critical roles in the future. Readiness is assessed
                                                                                               paths and development opportunities.
                              based on performance, growth potential, motivation, and
                              the support they may still need.
Page 18
                                                         Promoting Equal Opportunity for Leadership
                  Progression                                          Promotion                                                           Objectives

                                                                                                 1.   Structured and Efficient Process
 Ensures that employees see clear paths for advancement, Promotes fairness in                         Promotions are conducted at predetermined times within the annual cycle, following a
 promotions and progression, reducing potential biases and increasing trust in the system             structured and efficient process.
                                                                                                 2.   Transparency and Equal Opportunity
                                                                                                      Clear, fair, and transparent standards are applied for all employees, ensuring everyone
                                                                                                      understands the requirements and process for promotion
                                                            One-level increase in an
                                                                                                 3.   Alignment with Organizational Strategy and Needs
                                                            employee's job grade within
                                                                                                      Promotions are aligned with the organization’s long-term strategy and business requirements,
                                                            the same layer
                                                                                                      ensuring that each role is filled by the right person, in the right place, at the right time.
                                                                                                 4.   Enhanced Talent Management
                                                                                                      The process facilitates the development of high-potential employees by providing structured
                                                                                                      career advancement pathways, which help strengthen retention, motivation, and loyalty.
 Progression refers to the advancement of an employee’s job grade from a lower to a higher
 level without any change in position or title. It is granted as a form of recognition for the
 employee’s significant performance and / or capabilities that have a positive impact on their
 work unit / organization.



 Employee movement from
 one layer to a higher layer,
 which requires additional
 responsibilities and an
 expanded job scope



Promotion refers to the advancement of an employee’s job layer from a lower to a higher
layer, accompanied by an increase in the responsibilities attached to the position. This
promotion involves greater authority and accountability within the respective work unit.
Page 19
Improvement on Employee Turnover Rate




                        EMPLOYEE TURNOVER RATE




                  23%                      10%
                     2023                        9M25
Page 20
                                          ESG Framework


                                                     IBU
   Inisiator yang Adil dan                     Bumi yang Asri dan                      Utamakan Pelayanan
     Bertanggung Jawab                            Sejahtera                                  Pasien

   Menerapkan efektivitas                      Memberikan dampak
     tata kelola dalam                                                                   Meningkatkan kualitas
                                              positif bagi lingkungan
     menunjang kinerja                                                                    pelayanan pasien
                                                  dan pemangku
   keberlanjutan melalui                                                                 melalui dedikasi yang
                                                kepentingan melalui
       praktek yang                                                                          terbaik dan
                                               peningkatan kualitas
    bertanggung jawab.                                                                       terpercaya.
                                              hidup, serta penerapan
                                              prinsip keberlanjutan.

Fair and Responsible Initiator             A Sustainable and Prosperous Earth          Prioritize Patient Care
Implement effective governance to          Create a positive impact on the             Enhance patient care quality
support sustainable performance through    environment and stakeholders through        through the best and most trusted
responsible practices.                     improved quality of life and the            dedication
                                           application of sustainability principles.
Page 21
ESG - A Workplace that Cares About Breastfeeding
                    Mothers




             Breastfeeding Policy     Lactation Room
Page 22
3. CUSTOMER PERCEPTION & TRUST
• Continuous Improvement to Deliver Service Excellence
• Consistently Improving the Patient Journey
Page 23
             Continuous Improvement to Deliver Service Excellence


                                                                                                   RESULT:
 BMHS is committed to deliver service excellence through
                                                                 NPS rose from 82 to 87, highlighting stronger patient satisfaction and service
continuous training and development of medical and nursing                                        excellence.
                          competencies.

             In 2025, BMHS has arranged:




            >2600                   training activities
                                                                                       82                               87
  The training programs encompass NICU, PICU, medical
  ethics and patient care, surgical excellence, and more—
strategically designed to elevate nursing quality and clinical                          2023                            2025
                  standards across BMHS.

                                                                     Google Review ratings improved reflecting tangible gains in service
                                                                                   excellence and patient engagement.




                                                                                       4.2 4.4
                                                                                            2024               Sep-25
Page 24
Consistently Improving the Patient Journey




                                 BMHS continues to enhance patient
                                 communication.

                                 The   new         platform    introduces
                                 features    for     package      orders,
                                 emphasizing        transparency     and
                                 patient convenience.
Page 25
4. STRENGTHEN COE OF WOMEN & CHILDREN
• Pioneer in Women & Children Centers of Excellence
• Neonatal Intensive Care Unit (NICU)
Page 26
                              Pioneer in Women & Children Centers of Excellence




                                                                     Supported by 193 specialists and subspecialists
Comprehensive women and children’s care through:


OBGYN                         PEDIATRIC
                                                                                77                         46                    7
                              15
                                                                                                         PAEDIATRIC       PAEDIATRIC SURGERY




    5
                                                                        OBSTETRIC & GYNECOLOGY




            Subspecialties                    Subspecialties
                                (include Pediatric Surgery)
                                                                                 34                        29
                                                                        SUBSPECIALIST OBSTETRIC &   SUBSPECIALIST PAEDIATRIC
                                                                              GYNECOLOGY
Including fertility,           Specialized COE:
fetomaternal, gyneco           Pediatric Hemato Oncology,
oncology, social obstetric,    Pediatric Gastro Entero Hepatology,
urogynecology                  Alergy Immunology and Pediatric
                               Radiology
Page 27
Pioneer in Women & Children Centers of Excellence




  Growing contribution from Women & Children Excellence

               1%                 2%

                                                Pediatric
                      21%                 22%
               48%                51%           OBGYN

         26%                27%                 Pediatric Surgery



               9M24                9M25
Page 28
Neonatal Intensive Care Unit (NICU)

        Bunda’s hospital has been a leader in neonatal care and
        currently has 31 NICU beds.

        At RSIA Bunda Jakarta alone, the NICU is equipped with 10 Level 3 beds, treating
        approximately 250–300 high-risk newborns annually and serving as a key referral
        center for complex, including advanced respiratory support, transfusion,
        premature and surgical care, and other high-risk neonatal treatments. With a
        specialized transport team of NICU nurses and doctors, the unit provides advanced,
        continuous care for critically ill newborn.

        To offer comprehensive services, Bunda Hospitals also launched the Family Integrated
        Care (FICare) program, which enables parents to actively participate in their premature
        babies’ care and recovery. This family-centered approach strengthens bonding, supports
        breastfeeding, and improves clinical outcomes for high-risk newborns.




        “Referred by another hospital     “Born at 35 weeks with low birth       “Extreme Premature (born at 6
        to RSIA Bunda for intensive      weight, required NICU care. Under     months of pregnancy, weighing 900
        NICU care, now the baby is        medical care, development has        grams, required NICU care in RSIA
        growing well and very active.”   been remarkably fast — able to lift        BJ, now already 3.56 kg”
                                               head 90° at 7 weeks.”
Page 29
5. Leading Healthcare Innovation through Centers of
Excellence
• Leading Robotic Surgery with the 2nd-Generation System
• Reinforcing Excellence in Uro-nephrology and High-Value Kidney Transplant
  Services
• Skin Sparing Mastectomy, 1st in Southeast Asia
• Bunda Clinic: MRT Dukuh Atas
Page 30
     Leading Robotic Surgery in Indonesia

Experiences:                      Patients

12+      years
                                  800+
Pioneering robotic surgery in Indonesia since 2012 now revitalizing our capabilities with New
Robotic Surgery System since early 2025

BMHS’s COE for Advanced Robotic Minimal Invasive Surgery (ARMIS) COE is supported
by 16 certified specialist doctors in OBGYN, UROLOGY, ONCOLOGY, ENT, and
DIGESTIVE.
Page 31
            RSU Bunda Jakarta: Reinforcing Excellence in Uro-
          nephrology and High-Value Kidney Transplant Services


Kidney
Transplant
RSU Bunda Jakarta has successfully
performed



       6    procedures

   100% success rate
Page 32
       RSU Bunda Jakarta: Robotic Skin Sparing Mastectomy, 1st in Southeast Asia
Harapan Baru untuk Survivor Kanker Payudara melalui Pengangkatan Kanker dengan Mempertahankan Bentuk Alami Payudara




 •   Addresses the dual challenge of clinical complexity and aesthetic outcomes, redefining post-mastectomy reconstruction standards in Indonesia.
 •   Reinforces BMHS’s commitment to patient-centered innovation—focusing on both medical effectiveness and long-term quality of life.
Page 33
                   Bunda Clinic: MRT Dukuh Atas
Introducing the Urban Wellness Concept within Jakarta’s Dynamic Mobility Landscape


                                                Collaborative initiative with Jakarta Provincial
                                                Government, Health Office, and PT MRT Jakarta to
                                                expand preventive healthcare access and support
                                                the Jakarta Global City vision.

                                                Primary clinic offering four key services — Vaccination,
                                                Immune Booster, Mini MCU, and Outpatient care.
Page 34
6. Maximizing Current Asset Utilization
Page 35
Maximizing Current Asset Utilization

            TOTAL BEDS
        FROM          TO

        600           1000
Page 36

          

File

File Open PDF
Source IDX
Size5.34 MB
Published21 Nov 2025
Pages36
Characters40,325
Text sourceEmbedded text layer
OCR confidence—

Names mentioned 4 people and organisations named in the text · linked when the evidence is strong

possible org Bundamedik Tbk p.1 ×3
unresolved org COEs. Corp p.12
unresolved person Inisiator p.20
unresolved org PT MRT p.33

Extraction attempts how the parser did, and what it refused

Nothing structured was extracted from this document — the attempts below say why.

No extraction attempted yet.

↑↓ select ↵ open ⇧↵ see every result